3 Stocks Near 52-Week Highs Worth Selling

Stock indexes wrapped up their best January in 15 years, and nearly 1,000 stocks are within 6% of a new 52-week high. For optimists, these rallies may seem like a dream come true. For skeptics like me, they're opportunities to see whether these companies have actually earned their current valuations.

Keep in mind that some companies do deserve their current valuations. Qualcomm (Nasdaq: QCOM  ) , for instance, handily beat first-quarter EPS estimates last night and boosted its second-quarter outlook thanks to the continued strength of the Apple iPhone, for which Qualcomm is a supplier.

Still, other companies might deserve a kick in the pants. Here's a look at three companies that could be worth selling.

A gassy valuation
Not many natural gas producers are happy to see prices clocking in at decade-lows. For Cheniere Energy (AMEX: LNG  ) , that's a completely different story. The producer of liquefied natural gas has been using weak natural gas prices to secure long-term contracts through its Sabine Pass project in Louisiana. The concern I have is that despite these contracts, Cheniere still won't be turning a profit anytime soon.

Just look at Cheniere over the past decade -- zero annual profits and a cumulative free cash outflow of $2.7 billion in that time frame. Cheniere's infrastructure has also built up an enormous $2.96 billion pile of debt that has taken its book value from just shy of $1 in 2002 to nearly -$8.26 in the third quarter of 2011. To top things off, concerns were raised last year about whether or not one of Cheniere's subsidiaries was in default on its debt, and S&P sees a further cash crunch that could trigger a default this May. Too many questions, not enough bottom-line results if you ask me.

Where's the results?
EXACT Sciences
(Nasdaq: EXAS  ) and its Cologuard colon cancer diagnostic detection system is a clear case where the coolness of the science far exceeds the actual near-term results by a long shot.

EXACT Sciences is likely years away from having a viable product, despite having its colon cancer diagnostic test in late-stage clinical trials. Even if the product is approved, questions remain about its ability to successfully launch and market the diagnostic test. With no major partners funding its research and only $75 million in cash left, as Foolish colleague Rich Smith recently pointed out, it could run out of cash in three years. That's likely what prompted the company to bring another $27 million secondary offering to market last month. In fact, since 2008, EXACT Sciences' share count has ballooned by more than 55%. Personally, I wouldn't want this potential future destroyer of shareholder value anywhere near my portfolio until Cologuard is approved and the company proves it can effectively market the diagnostic test.

Clean energy, ugly performance
Sometimes I feel as if the clean energy craze has gotten out of hand. Maxwell Technologies (Nasdaq: MXWL  ) , a company that markets energy storage and power delivery products, is within spitting distance of a new 52-week high. Yet it has missed Wall Street's profit estimates in five of the last six quarters now, and eight of the past 10! Maxwell hasn't even turned an annual profit in any of the past 10 years, but its outstanding share count has increased in each and every year!

I've made it pretty clear recently that I don't care for the vast majority of solar companies -- but at least a company like First Solar (Nasdaq: FSLR  ) has remained profitable throughout the years, thanks to the high efficiency of its solar panels. For a company like Maxwell, it's going to take a lot more than the promise of profits and rising revenue to get me on board.

Foolish roundup
This week my three sell recommendations all share one thing in common: a long history of losses. It doesn't make much sense to chase a company higher until it can prove to you that it can regularly turn a profit. I'm so confident in my three calls that I plan to make a CAPScall of underperform on each one. The question now is: Would you do the same?

Share your thoughts in the comments section below and consider adding these three stocks to your free and personalized watchlist so you can keep track of the latest news with each company. Also, to avoid investing in stocks like these, consider getting a copy of our latest special report, "The Motley Fool's Top Stock for 2012." In this report, our chief investment officer details a play he dubbed the "Costco of Latin America." Best of all, this report is free for a limited time, so don't miss out!

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. He has no patience for perpetually underperforming stocks. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong. The Motley Fool owns shares of Apple, Qualcomm, and First Solar. Motley Fool newsletter services have recommended buying shares of Apple and First Solar, as well as creating a bull call spread position in Apple. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy that never needs to be sold short.

Read/Post Comments (4) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 02, 2012, at 2:57 PM, Kleeno65 wrote:

    I just sold all of my Exact Sciences, 'cause you said so...... NOT!!! You are indeed a "Fool".

  • Report this Comment On February 02, 2012, at 4:04 PM, NattyGuy wrote:

    Do you contributors even perform research before posting your opinions here? I am referring to "A gassy valuation" above. You are predicting a "defualt" on a loan that was paid off early in January of this year... The total outstanding debt you report in inaccurate too because of that. In my opinion they are in a stradegically advantageous place right now. Others see it that way too if one will just keep current with the publicized events transpiring.

    Cheniere Announces Early Repayment of the 2007 Term Loan

    HOUSTON, Jan. 6, 2012 /PRNewswire/ -- Cheniere Energy, Inc. ("Cheniere") (NYSE Amex: LNG) announced today that its indirect wholly owned subsidiary, Cheniere Subsidiary Holdings, LLC, has repaid in full the entire outstanding principal balance of $298.0 million plus accrued and unpaid interest payable under the 2007 Term Loan due May 31, 2012 ("Term Loan"). Cheniere used a portion of the net proceeds received from the equity offering transacted in December 2011 to repay the Term Loan. The aggregate repayment amount was $298.2 million, including the outstanding principal amount and accrued interest through January 5, 2012.

    The repayment of the Term Loan reduces the outstanding debt maturities of Cheniere due in 2012 to $204.5 million, releases the subordinated units of Cheniere Energy Partners, L.P. held as collateral for the Term Loan and results in the reduction of future interest obligations of $11.6 million that would have otherwise been payable through the Term Loan maturity. Cheniere's total outstanding indebtedness, excluding indebtedness of Cheniere Energy Partners, L.P. and its subsidiaries, has been reduced to $486.8 million.

  • Report this Comment On February 02, 2012, at 4:09 PM, blearynet wrote:

    This article appears to be just filler, with a titillating title and no substance at all.

  • Report this Comment On February 03, 2012, at 10:30 AM, UlyssesBenDover wrote:

    yes, sell Exact Sciences, any stock that's only gone up for three years as they move towards having a huge position in a huge market ought to be sold. Absolutely, sell Exact Sciences. The trend is not your friend with Exact.

    And the product they have on the market next year, hey, who wants to know before or very early that they have cancer. Not knowing until stage 2, 3 or 4 allows folks to do all that fun chemo and radiation so they can tell stories about it.

    I mean come on, Medicare wouldn't want something on the market that reduces billions in cancer treatment costs. Just because they approved it already, doesn't mean they think it should be used.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1771868, ~/Articles/ArticleHandler.aspx, 11/23/2014 7:20:53 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement